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Abstract: The majority of brain metastases originate from lung cancer, breast cancer and 
malignant melanoma. In order to reach the brain, parenchyma metastatic cells have to 
transmigrate through the endothelial cell layer of brain capillaries, which forms the 
morphological basis of the blood-brain barrier (BBB). The BBB has a dual role in brain 
metastasis formation: it forms a tight barrier protecting the central nervous system from 
entering cancer cells, but it is also actively involved in protecting metastatic cells during 
extravasation and proliferation in the brain. The mechanisms of interaction of cancer cells 
and cerebral endothelial cells are largely uncharacterized. Here, we provide a comprehensive 
review on our current knowledge about the role of junctional and adhesion molecules, 
soluble factors, proteolytic enzymes and signaling pathways mediating the attachment of 
tumor cells to brain endothelial cells and the transendothelial migration of metastatic cells. 
Since brain metastases represent a great therapeutic challenge, it is indispensable to 
understand the mechanisms of the interaction of tumor cells with the BBB in order to find 
targets of prevention of brain metastasis formation. 
Keywords: blood-brain barrier; cerebral endothelial cell; tight junction; paracellular 
transmigration; astrocyte; central nervous system; metastasis; breast cancer; lung  
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1. Introduction 
Brain metastases constitute a significant part of intracranial tumors. Only in the United States, about 
170,000 metastatic brain tumors are diagnosed annually [1], whereas primary tumors represent 17,000 
new cases/year. The majority of brain metastases originate from lung cancer (40%–50%), breast 
cancer (15%–25%) and malignant melanoma (5%–20%) [2]. Among these tumors, melanoma is the 
one which metastasizes to the brain with one of the highest frequencies: brain metastases are 
diagnosed in 40%–50% of the cases, which, after autopsy, increase with an additional 30%–40%. 
Melanoma is diagnosed in six–40 cases/100,000 inhabitants/year, causing 4% of all skin cancers and 
being responsible for 74% of skin cancer deaths. Of melanoma brain metastases, 49% are 
intraparenchymal, 22% are leptomeningeal and 32% are dural [3]. The presence of a brain metastasis 
represents a very poor prognosis for the patient, the five-year survival rate being below 10%. The 
number of diagnosed melanoma cases is constantly increasing [4]. 
Breast cancer is the second most common type of cancer and worldwide causes more than half a 
million deaths annually. Breast cancer metastases to the central nervous system (CNS) include the 
clinically distinct situations of multiple brain metastases (78%), solitary brain metastasis (14%) and 
leptomeningeal metastases (8%) [5]. CNS metastases occur in 10%–16% of stage IV patients, while 
they are found in 30% of patients in autopsy series [5]. 
The most common cause of brain metastases is lung cancer. Interestingly, small cell carcinomas, 
which are only 20% of all lung cancers, account for 50% of brain metastases from lung cancer. About 
10% of the patients having small cell lung carcinoma initially present with brain metastases. The  
two-year cumulative risk rises to ≥50%, and CNS metastases are found in up to 65% of patients at 
autopsy. The median survival time after brain metastasis diagnosis is four to five months [6]. 
Formation of metastases in distant organs involves blood or lymphatic transport of cancer cells. 
Since the CNS lacks a lymphatic system, the only possibility for cancer cells to reach the brain is via 
the blood stream. Brain metastases can be formed both in the parenchyma and the meninges. 
Leptomeningeal metastases resulting from solid tumors occur late and usually coexist with CNS 
parenchymal disease. Metastatic cells invading the CNS parenchyma, however, have to pass the  
blood-brain barrier (BBB). 
2. The Blood-Brain Barrier 
2.1. Cellular Structure of the BBB 
The blood-brain barrier (BBB) is located at the level of cerebral capillaries in the forefront of the 
defense line of the CNS and restricts the free movement of solutes and cellular elements between the 
systemic circulation and neuronal tissue. The BBB is involved in the pathogenesis of a large number of 
CNS disorders [7,8]. The most important cellular elements of the BBB are endothelial cells, astrocytes 
and pericytes forming the neurovascular unit (Figure 1). 
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Figure 1. Schematic structure of the blood-brain barrier. Cerebral endothelial  
cells—coming in contact with pericytes and astrocytes—form the morphological basis of 
the blood-brain barrier. Endothelial cells are interconnected by a continuous line of tight 
junctions. The insert shows the molecular structure of the junctional complex. TJ = tight 
junction; AJ = adherens junction. 
 
2.1.1. Endothelial Cells 
Endothelial cells lining brain capillaries are thin, flat cells interconnected by tight junctions [9] and 
characterized by a high number of mitochondria [10] and low number of caveolae [11]. The contact 
region of brain endothelial cells is usually overlapping, and the apical region of cell membranes is 
interconnected by a continuous line of tight junctions limiting the free transport of different solutes and 
cellular elements. Cerebral endothelial cells share common features with other endothelia (presence of 
factor VIII, high alkaline phosphatase and γ-glutamyl transpeptidase activity, uptake of acetylated-low 
density lipoprotein) and epithelia as well (high transendothelial electrical resistance (TEER), 
continuous line of tight junctions, low level of pinocytosis), these latter being indispensable for the 
barrier function. 
2.1.2. Pericytes 
Pericytes are located in the duplication of the basement membrane, in close contact with endothelial 
cells. Even gap junctions have been described between the two cell types [12]. In the rat brain, pericyte 
coverage of the capillaries varies between 22% and 32% [13] and the ratio of pericyte/endothelial cells 
is about 1/3–5 [14]. Pericytes are contractile cells able to synthesize a plethora of biologically active 
substances. Although the exact function of pericytes in the formation and function of the BBB is 
insufficiently understood, they can participate in the regulation of blood flow, endothelial proliferation, 
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angiogenesis or inflammatory processes. Absence of pericytes leads to endothelial hyperplasia, 
abnormal vasculogenesis [15] and increased BBB permeability [16]. Pericyte-endothelial cell interactions 
were found to be critical in the regulation of the BBB during development [17]. 
2.1.3. Astrocytes 
Astrocytes play a crucial role in the induction of blood-brain barrier properties (reviewed in: [18,19]). 
Astrocytic endfeet nearly completely ensheath the capillary walls, thereby covering not only 
endothelial cells, but also the intimately associated pericytes [20]. The coverage is not complete, 
allowing a direct contact of nerve endings with the basal membrane [21,22]. Astrocytic endfeet express 
a high level of several specific proteins at their capillary side, like glucose transporter 1,  
P-glycoprotein (P-gp), aquaporin-4, connexin-43 and Kir 4.1 K+ channel. 
2.1.4. Other Cells of the Neurovascular Unit 
In the adult mammalian brain, neurons are usually not in direct contact with cerebral endothelial 
cells. So far, it is unclear whether there are signals from endothelial cells to neurons and vice versa, 
which could be important for brain homeostasis or for neuronal function. Such communication could 
be accomplished by the presence of neurotransmitter receptors on endothelial cells, as observed 
previously [23]. 
Microglia is another cell type that is in close contact with cerebral vessels. The role of microglia in 
the neurovascular unit is still poorly understood, and sometimes controversial. They may potentiate 
BBB damage during neuroinflammation [24]; however, a beneficial effect has also been reported in 
response to ischaemic brain injury [25]. 
2.1.5. The Basement Membrane 
The basement membrane is a specialized extracellular matrix covering endothelial cells from the 
outside. Its main protein components include collagen (especially type IV), fibronectin, laminin, 
tenascin and proteoglycans [11]. The extracellular matrix serves as an anchor for endothelial cells 
through the interaction between laminin and other matrix proteins and endothelial integrin receptors [26]. 
Besides signaling events [27], the cell-matrix interaction also modulates TJ protein expression [28]. 
Furthermore, the basal membrane plays an important role in cell adhesion and migration and may form 
a barrier for macromolecular and cellular migration. Moreover, the basal membrane was shown to be 
essential for the survival of cancer cells during brain colonization [29]. 
2.2. Molecular Structure of the BBB 
Transport across the brain endothelium is strictly limited through a four-fold defense line  
(for review see: [30]): paracellular barrier (represented by interendothelial junctions); transcellular 
barrier (assured by the low level of endocytosis and transcytosis); enzymatic barrier (including 
acetylcholinesterase, alkaline phosphatase, γ-glutamyl transpeptidase, monoamine oxidases and drug 
metabolizing enzymes); and efflux transporters (ABC-B1, -C1, -C4, -C5 and -G2). Small gaseous 
molecules, such as O2 and CO2, can freely diffuse through the lipid membranes, and this is also a route 
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of entry for small lipophilic agents, including barbiturates, nicotine and ethanol. However, specific 
blood-to-brain influx transport systems exist to supply nutrients, like glucose, amino acids and 
nucleotides, which cannot freely diffuse to the brain. 
The paracellular permeability is mainly regulated by the tight junctions (TJs) between endothelial 
cells (Figure 1). Key components of the tight junctions are the transmembrane proteins, which  
form three protein families. These are the four transmembrane proteins (occludin, claudins, 
tricellulin/marvelD2, marvelD3), which are perhaps the most important from the point of view of 
paracellular permeability, molecules belonging to the immunoglobulin superfamily (JAM—Junctional 
adhesion molecule; CAR—Coxsackie and adenovirus receptor; ESAM—Endothelial cell-selective 
adhesion molecule) and non-immunoglobulin-like molecules with a single transmembrane domain 
(CRB3—Crumbs homolog 3; Bves—Blood vessel epicardial substance). Best characterized in cerebral 
endothelial cells are occludin, claudins and JAMs [31]. 
2.2.1. Transmembrane TJ Proteins 
2.2.1.1. Occludin 
Occludin, the first identified transmembrane TJ protein [32], is a 65 kDa molecule. It is 
characterized by four transmembrane regions, two extracellular loops, a shorter N-terminal and a 
longer C-terminal cytoplasmic domain. The two extracellular loops are rich in tyrosine and glycine, 
playing a role in sealing the junctions [33,34], while the C-terminal region is important in the 
interaction with other junctional proteins. 
2.2.1.2. Claudins 
Claudins, first described by Furuse et al. [35], are small proteins (20–27 kDa), which show a similar 
membrane topology to occludin (short N-terminal cytoplasmic region, two extracellular loops, short  
C-terminal tail); however, there is no sequence homology between them. Interactions of claudins are 
largely determined by the C-terminal intracellular region, which contains PDZ binding domains. 
Furthermore, claudins are able to form homophylic interactions as well needed for the formation of 
tight junction strands [36]. The principal claudin in brain endothelial cells is claudin-5, but other 
claudins (especially claudin-1, -3 and -12) have also been detected [37]. The exact role of individual 
claudins is not known; absence of claudin-5 leads to a selective opening of the BBB to molecules 
smaller than 800 Da [38]. Claudins play an important role in several pathologies, including cancer [39]. 
2.2.1.3. Immunglobulin-like Molecules 
Junctional adhesion molecules (JAMs) are single-span molecules belonging to the immunoglobulin 
superfamily characterized by homophilic binding and two extracellular loops, first described by 
Martin-Padura et al. [40]. Brain endothelial cells express mainly JAM-1 (JAM-A) and JAM-3  
(JAM-B) [41], but also JAM-C. They are involved in the extravasation of leukocytes. Endothelial cells 
also express ESAM (endothelial cell-selective adhesion molecule), another immunoglobulin-like 
molecule localized to the TJs. JAM-C and ESAM have been shown to promote melanoma lung 
metastasis formation [42,43]. 
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2.2.1.4. Other Transmembrane Proteins of the TJs 
In epithelial cells several additional components of the TJs have been identified, the expression/role 
of which has not been characterized in endothelial cells. These molecules include tricellulin, CAR, 
marvelD3 and Crumbs homolog 3 (CRB3). 
2.2.2. Peripheral Proteins of Tight Junctions 
2.2.2.1. PDZ Domain Containing Proteins 
2.2.2.1.1. Zonula Occludens (ZO) Proteins 
To our present knowledge, there are three members of the zonula occludens family: ZO-1 [44],  
ZO-2 [45] and ZO-3 [46]. ZO-3 seems to be less important in the formation of endothelial tight 
junctions [47]. Common structural features of the ZO family include three PDZ domains in the  
N-terminal region, a SH3 (Src homology 3) domain and an enzymatically inactive GUK (guanylate 
kinase) domain. ZO proteins are important scaffold proteins, but are essential in signaling processes as 
well [48,49]. 
2.2.2.1.2. Other Proteins Containing PDZ Domain 
The cytoplasmic plaque of the TJs contains other PDZ domain containing proteins as well. These 
include AF6/afadin, MUPP1 (multi-PDZ-domain protein), MAGI (membrane associated guanylate 
kinase inverted) -1, -2 and -3 and PAR-3 and -6. These proteins also bind other proteins of the 
junctional complex, but their role in the regulation of endothelial TJs has not been characterized yet. 
2.2.2.2. Plaque Proteins without PDZ Domain 
Besides PDZ domain proteins, the junctional plaque contains cingulin, its homologue 
paracingulin/JACOP and a large number of signaling molecules. 
3. Mechanisms of Interaction of Tumor Cells with Brain Endothelial Cells 
The BBB, which represents the tightest endothelial barrier in the organism, forms an obstacle for 
the traffic of not only solutes, but cells as well. Penetration of cells into the CNS is highly limited by 
the BBB; therefore, it is surprising that some cancer types give metastases preferentially to the brain. 
This phenomenon draws the attention to the possibility that besides being a barrier, the BBB may have 
a supportive role in the metastasis formation as well. Indeed, cerebral endothelial cells can actively 
take part in the transmigration process and may even facilitate the penetration of metastatic cells or can 
provide an ideal milieu for transmigrated cells to survive in their close proximity. This can be due to 
the fact that after crossing the barrier, metastatic cells are protected from the immune surveillance of 
the organism and cellular components of the BBB may release substances favorable for metastasis 
growth, as discussed in the forthcoming chapters. 
Despite an impressive amount of data regarding motility and migration of cancer cells, information 
about the mechanisms involved in the migration of cancer cells across endothelial barriers is limited. 
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This is especially true for the BBB. The process of transendothelial migration has been intensively 
studied using immune cells. Although the steps of transmigration (rolling, adhesion and 
transmigration/diapedesis) may show some similarities, due to different physiological, molecular and 
mechanical characteristics of immune and metastatic cells, there may be significant differences [50]. 
3.1. Morphological Aspects 
Arrest of tumor cells was found to take place at the level of capillaries and postcapillary venules, 
where the diameter of the vessels is comparable to those of the metastatic cells, predominantly at 
vessel branches [51,52]. 
The extravasation process of tumor cells seems to have organ-specific elements. Tumor cells need a 
significantly longer time to extravasate into the brain than into other organs. In the brain, reaching an 
extraluminal position was found to take two days in case of lung and two-seven days in case of breast 
cancer cells [51,53]. Kienast et al. [52] have observed that melanoma and lung cancer cells have 
extravasated up to 14 days; however, cancer cells that later proliferated into macrometastases had left 
the blood vessel by the third day. The diapedesis itself is probably rapid [53], but arrested cancer cells 
need to survive within the brain vasculature for a significantly longer time than in other organs [51]. 
This seems to be a rate limiting step only in the brain. Intravascular proliferation preceding 
transendothelial migration seems to characterize only some cell lines with high affinity for the brain [51]. 
Cancer cells arrested in the brain vasculature initially assume an elongated shape and, later, round 
up and stretch the vessel walls [51]. During the transmigration process, tumor cells show intra- and 
extra-vascular parts with a narrowing at the level of the vascular wall, suggesting that the 
transmigration takes places through holes in the endothelium. In addition, tumor cells produce 
extensions and retractions of the extravascular protrusions, indicating that the transmigration process is 
a dynamic one [52]. 
The contribution of endothelial cells seems to be organ-specific as well: while in the lung and liver, 
endothelial cells migrate onto the surface of the tumor cells, in the brain, endothelial cells do not cover 
tumor cells; instead, a retraction of endothelial cells was observed [53]. It is a question of debate 
whether tumor cells leave the endothelium intact or destruct the vessel wall during diapedesis. Breast 
cancer cells were found to transmigrate at sites of discontinuity of the vessel wall, but no endothelial 
apoptosis or hypoxia was observed [51]. Using an in vitro system, we have observed that melanoma 
cells damaged the integrity of the brain endothelial monolayer, induced endothelial apoptosis and 
decreased the transendothelial electrical resistance [54]. It was suggested, however, that the barrier can 
repair after passage of metastatic cells [55]. On the other hand—although extravasation of single cells 
is the dominant mechanism of brain metastasis formation—in some cases, intravascular proliferation 
of tumor cells may lead to the complete obstruction of the vessel and, finally, to the disruption of the 
BBB [56]. 
After diapedesis, endothelial cells are indispensable for the proliferation of metastatic cells, 
formation of the tumor vasculature (by angiogenesis or vessel cooption) and of the blood-tumor 
barrier. Proliferation of metastatic cells in the brain was only observed when transmigrated metastatic 
cells remained in close contact to the basolateral side of endothelial cells, in a position similar to 
pericytes [52]. Moreover, breast cancer cells extravasated into the brain were shown to get aligned 
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along the blood vessels, on the extraluminal side [56]. According to our observations, after completing 
the transendothelial migration process, melanoma cells continue their movement beneath the 
endothelial cell layer [54]. Some perivascularly located single metastatic cells (or clusters up to three) 
can remain dormant for longer periods [52]. These cells can constitute a source for the formation of 
new metastases. 
The long-lasting close contact of extravasated tumor cells with the endothelium may have two 
reasons. First, the vascular basement membrane supports the growth of the metastasis prior to the 
formation of the tumor vasculature [29]. This is the so-called vessel cooption, which seems to be 
characteristic to breast cancer and melanoma, but not lung cancer cells [29,52,57]. In contrast to 
melanoma and breast cancer, lung cancer metastases were shown to present early angiogenesis [52]. 
Second, cancer cells might benefit from the protection of the BBB against anti-tumoral immune 
cells and chemotherapeutics. It is a question of debate whether the vascular network of the metastases 
exhibits altered permeability. The blood-tumor barrier was suggested to remain intact in small 
metastases, its integrity altering only when larger lesions are formed [55]. Others state that in breast 
cancer metastases, the blood-tumor barrier has an increased permeability, which poorly correlates with 
the size of the lesion. However, the barrier remains sufficiently intact to impair drug delivery [58]. 
The morphological aspects of the interaction of tumor cells with the brain endothelium are 
summarized in Figure 2a. 
3.2. Selectively Expressed Genes and Proteins in Brain Metastatic Cells 
One of the crucial issues in the goal to prevent or reduce the number of metastases is the 
understanding of molecular mechanisms of organ-specific metastases. A key determinant of the site of 
metastasis formation is the gene or protein expression profile of metastatic cells with affinity to a 
specific organ. Specific gene expression combinations may determine the ideal conditions in which the 
tumor cell can survive and divide, thus determining preferential target organs. On the other hand, in 
the case of the brain—which has a specific vasculature lined by BBB endothelial cells—these 
expression profiles may determine the interaction of metastatic cells with the endothelium as well. 
In one of the first attempts to identify differentially expressed genes, the authors compared gene 
expression of primary lung adenocarcinoma (a frequent subtype of non-small cell lung carcinoma) 
with brain metastases originating from these tumors. They have found considerable differences: of 
23,040 genes tested, 244 showed a different expression level, including genes coding for plasma 
membrane proteins, cellular antigens and cytoskeletal proteins, which may modulate cell-cell 
interactions [59]. 
Brain metastases of lung adenocarcinoma were evaluated in another study as well, by comparing 
the gene expression profile of metastatic brain tumors originating from lung adenocarcinoma with that 
of healthy lung. Using cDNA microarray technology, 1,561 differently expressed genes were found. 
The overexpression of certain genes associated with invasion and metastasis (PTEN, MMP1), adhesion 
(integrin α3 and fibronectin1), angiogenesis (VEGF) and cell migration (Rho GTPase) was validated 
by real-time PCR [60]. 
A correlation analysis of frozen samples from 142 patients diagnosed with non-small cell lung 
carcinoma revealed three genes that were associated with brain metastases. Expression of these three 
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genes was predictive for brain metastases: FALZ (fetal Alzheimer antigen), KIFC1 (kinesin family 
member involved in cell proliferation) and N-cadherin. While the first two may play a role in the 
growth of metastases in a neural environment, expression of N-cadherin may play a role in the 
interaction of metastatic cells with brain endothelial cells as well, which are also able to express  
N-cadherin [61]. 
In another study, a multidimensional proteomic analysis was used to examine the protein expression 
profiles of breast cancer cells, by comparing the parental cell line and its brain or bone homing 
variants. More than 300 proteins were found to be uniquely regulated in brain metastatic breast cancer 
cells, most of which are involved in cellular metabolism and cell stress response. These data reflect the 
adaptation of the tumor cells to aerobic glycolysis, which is more favorable in the brain environment [62]. 
Figure 2. Mechanisms of interaction between tumor cells and the brain endothelium.  
(a) Morphological aspects and upregulated genes and proteins involved in brain metastasis 
formation of melanoma, breast and lung cancer; (b) Molecular mechanisms. Several 
adhesion molecules were shown to be involved in the adhesion of tumor cells to the brain 
endothelium. Proteases and other soluble factors secreted by tumor cells may induce the 
disruption of the tight junctions. 
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Figure 2. Cont. 
 
(b) 
Brain and bone metastases of breast cancer cells were compared by Klein et al. [63] as well. 73 
differentially expressed genes were found, with 51 genes having significantly higher expression in 
brain metastases. Among the genes overexpressed in the brain, several encode proteins involved in 
translation, metabolism, signal transduction and transport, but there are adhesion molecules as well, 
which may play a role in the interaction of metastatic cells with the cerebral endothelium. 
Investigating breast cancer brain metastases, Palmieri et al. [64] have revealed downregulation of 
six genes and upregulation of two: hexokinase and laminin-γ3. 
Finally, in a genomewide comparative study, the authors have found 243 genes over- or  
under-expressed in the brain metastatic population of breast cancer cells. Further analysis identified 
COX2, the epidermal growth factor receptor ligand HBEGF, and the α2,6-sialyltransferase 
ST6GALNAC5 as important determinants of transmigration of breast cancer cells through the BBB. 
While COX2 and HBEFG were also found in lung metastases, ST6GALNAC5 was found to be 
specific to brain metastases. ST6GALNAC5 is a brain-specific sialyltransferase and may directly 
influence breast cancer cell adhesion to cerebral endothelial cells [65]. 
Summarizing the results, one can observe that the different studies have found some members of 
gene classes involved in adhesion and proliferation to be increased in brain metastatic tumor cells 
(Figure 2a). It is noteworthy, however, that there is a low overlap between the different sets of genes 
identified. Which of these are involved in the interaction of tumor cells and brain endothelial cells still 
needs to be elucidated. 
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3.3. Transmigration Routes: Role of the Proteins of the Tight Junctions 
Transendothelial migration of cells can occur by two routes: the paracellular pathway (through the 
interendothelial junctions) and the transcellular one (through single endothelial cells). Leukocytes are 
able to use both routes in the brain endothelium as well [66,67], and the molecular mechanisms 
involved in the paracellular and transcellular migration pathways of leukocyte diapedesis have been 
intensively studied (reviewed in: [68,69]). Much less is known about the transmigration routes of 
tumor cells, especially in the brain. 
Paracellular transmigration of metastatic cells is possible only with the involvement of endothelial 
tight junctions and junctional proteins. In a recent study using an in vitro model of the BBB, we have 
observed that different types of melanoma cells were able to reduce transendothelial electrical 
resistance (TEER), which is a widely used indicator of junctional integrity [54]. Moreover, not only 
the presence of metastatic cellular elements, but their conditioned media, was also able—although to a 
lesser extent—to reduce TEER. Immunfluorescence studies revealed that the disruption of the TJs 
stands at the molecular basis of the increased permeability, reflected by a discontinuous staining of 
claudin-5 and ZO-1. After longer coculture times, melanoma cells were able to make holes in the 
endothelial monolayer, which could be used by other metastatic cells. The mechanisms by which 
metastatic cells are able to disrupt TJs are incompletely understood; however, proteolytic processes 
probably play an important role. 
On the other hand, it is not excluded that tumor cells might also use the transcellular pathway; 
especially as brain endothelial cells are interconnected by tight junctions, which seal the intercellular 
way of transport. So far, transcellular migration of tumor cells has only been described in the case of 
intravasation of breast cancer cells into an artificial vascular network prepared from calf pulmonary 
artery endothelial cells [70]. 
3.4. Surface Molecules Mediating Different Steps of Tumor Cell Extravasation in the Brain 
Adhesion and junctional molecules involved in tumor cell-endothelial cell interaction and 
metastasis formation are weakly characterized and even less is known about brain endothelial-specific 
mechanisms. It is well known that tumor cells are able to partly mimic the molecular mechanisms of 
leukocyte-endothelial interaction occurring during inflammation. The steps of transendothelial 
migration of leukocytes and tumor cells are principally the same, i.e., rolling, adhesion and diapedesis; 
however, on the molecular level, the transmigration process of tumor cells has been much less 
described [50]. In this interaction, surface molecules of both endothelial and tumor cells might be 
involved (Figure 2a). Moreover, tumor cells were shown to indirectly use the adhesion molecules of 
leukocytes and platelets, by attaching to them and using them as bridges to the endothelium, making 
the molecular aspect even more complex [71,72]. In this chapter, we review the surface molecules of 
both endothelial and tumor cells involved in the interaction of tumor cells with brain endothelial cells. 
3.4.1. The Role of Selectins and Selectin Ligands 
Selectin-dependent mechanisms mediate tethering and rolling of leukocytes during the first steps of 
extravasation. Cancer cells, similar to leukocytes, express selectin ligands, which may play an 
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important role in their adhesion to endothelial cells. Selectin-dependent mechanisms are also important 
in the interaction of tumor cells with platelets and leukocytes, which facilitate the attachment of tumor 
cells to the vessel wall. The role of selectins in brain metastasis formation is largely uncharacterized.  
Anti-E-selectin antibodies were shown to partly inhibit adhesion of primary prostate carcinoma cells to 
brain endothelial cells [73]. Moreover, heparin—which inhibits not only coagulation, but selectin-mediated 
interactions as well—was shown to delay melanoma brain metastasis formation. Therefore, it has been 
suggested that heparin might have an anti-metastatic neuroprotective role, which might depend on 
selectins [74]. 
3.4.2. Integrins Involved in the Interaction of Tumor Cells with the Brain Endothelium 
Integrins are heterodimeric proteins consisting of a α and a β subunit that mediate cell-cell and  
cell-extracellular matrix interactions. They facilitate the firm adhesion of leukocytes to the 
endothelium. Several integrins were shown to be involved in cancer progression, metastasis formation, 
transendothelial migration of tumor cells and angiogenesis in different metastatic sites. Activation of 
integrin αvβ3 was observed to support efficient brain metastatic growth of breast cancer cells through 
continuous upregulation of VEGF, without influencing the growth of primary lesions [75]. Moreover, 
intetumumab, an anti-integrin αv monoclonal antibody, prevents brain metastasis formation of breast 
cancer cells [76]. Interaction of breast cancer cells with the brain endothelium might also be dependent 
on integrin β4. Integrin β4 signaling is involved not by directly promoting the adhesion of tumor cells 
to the endothelium, but by enhancing the HER2-dependent expression of VEGF, which induces the 
disruption of interendothelial junctions [77]. In the case of non-small cell lung cancer, the interaction 
of integrin α3β1 and laminin was suggested to play an important role in brain metastasis formation [78]. 
Blockade or loss of β1 integrin in mammary carcinoma cells prevents metastasis establishment and 
growth of the tumor cells in the CNS [29]. 
3.4.3. The Role of the Immunglobulin Superfamily of Cell Adhesion Molecules 
Endothelial cells express several adhesion molecules belonging to the immunoglobulin (Ig) 
superfamily, including members of the intercellular adhesion molecules (ICAMs), vascular-cell 
adhesion molecule (VCAM-1), platelet-endothelial-cell adhesion molecule (PECAM-1) and junctional 
adhesion molecules (JAMs). These are essential in immune response and inflammation, but some of 
them were also shown to be involved in the interaction of vascular endothelial and tumor cells and 
formation of metastases. Anti-VCAM-1 antibodies were shown to partly inhibit adhesion of primary 
prostate carcinoma cells to brain endothelial cells [73]. Moreover, establishment of pulmonary 
melanoma metastases was found to be followed by increases in VCAM-1 expression in organs 
frequently affected by melanoma metastases, including the brain [79]. In a recent paper, ICAM-1 and 
VCAM-1 were shown to play a crucial role in polychlorinated biphenyl-mediated enhancement of 
brain metastasis formation of lung carcinoma cells [80]. NCAM was shown to be highly expressed in 
the primary tumors of brain metastasis patients [81]; However, brain metastases were found to lose 
NCAM expression [82]. This may suggest that NCAM is important for the formation of brain 
metastasis (e.g., for transendothelial migration of tumor cells into the brain) and not for the survival or 
proliferation of metastatic cells in the brain environment. 
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3.4.4. Cadherins 
Cadherins are Ca2+-dependent cell adhesion molecules fundamental in tissue organization. Cadherin 
dysfunction is involved in tumor progression and metastasis formation. Loss of expression of  
E-cadherin induces epithelial-mesenchymal transition in carcinoma cells, which initiates an increase in 
cell motility and metastasis formation. In metastatic lesions, a re-expression of E-cadherin has been 
observed, which plays an important role in the proliferation of tumor cells at the metastatic site. 
Correspondingly, metastatic brain tumors were shown to express high levels of E-cadherin [83–85], 
while low expression of E-cadherin in primary non-small cell lung carcinomas was shown to correlate 
with increased risk for the development of brain metastasis [86]. In non-small cell lung carcinomas, the 
expression level of N-cadherin was observed to be highly predictive of brain metastasis formation [61]. 
Since transendothelial migration of melanoma cells through human lung microvascular endothelial 
cells was found to involve N-cadherin-mediated adhesion [87], a similar mechanism is possible in the 
case of brain endothelial cells as well. N-cadherin was shown to be recruited to the contact sites 
between transmigrating melanoma cells and pulmonary endothelial cells, followed by its Src  
kinase-mediated phosphorylation and dissociation of β-catenin from N-cadherin [88]. 
3.4.5. Tetraspanins 
Several members of the tetraspanin superfamily, including CD9, CD81 and CD151, might localize 
at the tumor cell-endothelial cell heterologous contact area. Among these, endothelial CD9 was shown 
to actively redistribute to points of melanoma insertion, and anti-CD9 antibodies were found to inhibit 
migration of melanoma cells through HUVEC monolayers [89]. CD151-null mice showed a markedly 
diminished number of experimental lung metastasis after injection of Lewis lung carcinoma or B16F10 
melanoma cells [90]. Similar mechanisms might be involved in the transmigration of tumor cells 
through the BBB as well. 
3.4.6. Melanotransferrin 
Melanotransferrin has been identified as a surface molecule on melanoma cells. Expression of 
melanotransferrin was found to correlate with increased transmigration of melanoma cells through the 
BBB, while blocking melanotransferrin significantly reduced transmigration. In mediating the effect of 
melanotransferrin, the plasmin-metalloproteinase system could be involved [91]. 
3.5. Soluble Factors Affecting Brain Metastasis Formation 
Tumor cells secrete several factors that may enhance their migration through the brain endothelium 
(Figure 2b). Brain-derived soluble factors may also play a significant role in the formation of brain 
metastases. This may be true especially in the case of melanoma, where the high proportion of brain 
metastases may be due to a “homing” influence [92], because melanocytes and the nervous system 
share a common embryologic (ectodermal) origin. 
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3.5.1. Neurotrophins 
Neurotrophins (NTs: NGF, BDNF, NT-3 and NT-4/5) are growth factors promoting neuronal 
survival, differentiation and cell death. Invasive and survival properties of CNS-metastatic melanoma 
cells were shown to be dependent on the presence of particular NTs that can be secreted by different 
cell types within the CNS. Brain metastatic melanoma cells may induce the production of brain NTs 
that aid in the survival and invasion of melanoma cells in the CNS [93]. In addition, NGF enhances the 
production of extracellular matrix-degradative enzymes in melanoma cells [92]. 
In the brain, NTs and NT receptors are known to be expressed by neurons and astrocytes. However, 
recent data suggest that NT release and signaling in the CNS may not be restricted to these two cell 
types. Murine and rat brain endothelial cell lines were shown to express NGF, BDNF and two NT 
receptors (TrkA and p75) [94,95]. Furthermore, pericytes are also able to express NGF and BDNF [96]. 
Therefore, one can speculate whether NTs play a role not only in the survival and proliferation of 
metastatic melanoma cells in the CNS, but in their migration through the BBB as well. 
3.5.2. Chemokines 
An important role in the formation of brain metastases seems to have chemokines and their 
receptors as well. In a recent comprehensive study, melanoma cells were shown to express a whole set 
of chemokine receptors, including CCR3, CCR4, CXCR3, CXCR7, CX3CR1 and membrane 
CX3CL1. Among these receptors, the expression of CCR4 was found to be significantly higher in a 
brain metastatic melanoma variant. Activation of CCR4 by its ligand CCL22 induced a specific Akt 
phosphorylation pattern, suggesting that specific signaling may be related to brain metastasis 
formation [97]. Moreover, brain-derived soluble factors were able to upregulate the expression of 
CCR3 and CCR4 in melanoma cells and enhanced the transmigration of melanoma cells through a 
monolayer of cerebral microvascular endothelial cells [98], further indicating that the brain 
microenvironment is not only important for the growth of already formed brain metastases, but also for 
the transmigration of melanoma cells through the BBB. Chemokines seem to be important in the brain 
metastasis formation of breast cancer cells as well, since the CXCR4/SDF1 signaling pathway was 
shown to have a decisive role in the migration of breast cancer cells through brain endothelial 
monolayers [99]. 
3.5.3. Vascular Endothelial Growth Factor and Its Receptors 
Being a key modulator of angiogenesis, VEGF is a well-established factor in the growth of 
metastases. However, VEGF secreted by extravasating tumor cells may be involved in the 
transmigration process as well, mainly by enhancing the permeability. In breast cancer cells, HER2 
increases VEGF protein production, which induces the disruption of interendothelial junctions [77]. In 
addition, VEGF was shown to increase the adhesion of highly metastatic MDA-MB-231 breast cancer 
cells to brain endothelial monolayers and to enhance their transmigration through an in vitro BBB 
model [100]. It has also been shown that small cell lung cancer cell-derived placental growth factor 
activates the VEGFR1/Rho/ERK signaling pathway in cerebral endothelial cells, resulting in the 
disassembly of tight junctions and promoting transendothelial migration [101]. 
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3.6. Proteases Involved in the Formation of CNS Metastases 
Proteolytic enzymes may play a role in several steps of metastasis formation, including invasion at 
the primary tumor site, intravasation, extravasation and metastatic colonization. Different proteolytic 
enzymes have been implicated in brain metastasis formation and migration of tumor cells through 
blood-brain barrier endothelial cells. The proteases involved are matrix metalloproteinases (MMPs), 
serine proteases and heparanase. These enzymes are mainly secreted by tumor cells; however, 
endothelial cells or astrocytes might also be induced by tumor cells to express proteases. 
3.6.1. The Role of Matrix Metalloproteinases in the Formation of Brain Metastases 
Several results suggest that MMP-2 plays a key role in the brain metastasis formation of breast 
cancer cells [102–104], melanoma [105] and leukemic cells [106]. MMP-3 and MMP-9 are also 
implicated in the development of breast cancer brain metastases [103]. In addition, MMP-1 and MMP-9 
were shown to be overexpressed in brain-seeking breast cancer cells in comparison with bone-seeking 
variants [107], while expression of MMP-2 and MMP-9 was found to be upregulated in breast cancer 
cells treated with angiotensin II, probably contributing to the increased migration through brain 
endothelial cells [108]. MMP-9 was found to be overexpressed by brain metastatic lung 
adenocarcinoma cells [109]. 
Regarding transendothelial migration of tumor cells through the BBB, MMPs might have special 
importance, because TJ proteins can be targets of MMP degradation. MMP-induced disruption of TJs 
was shown to promote invasion of tumor cells into the CNS [106]. Interestingly, not only tumor cells 
themselves produce MMPs, but they are able to induce the expression of proteases in brain endothelial 
cells, e.g., MMP-2 was shown to be induced in brain endothelial cells after coculture with breast 
cancer cells [110]. In this study COX-2 and MMP-2 produced by cerebral endothelial cells was found 
to facilitate the extravasation of breast cancer cells across the BBB. 
3.6.2. Other Proteases 
ADAM-9, a member of the “a disintegrin and metalloprotease” (ADAM) family was found to be 
overexpressed in highly brain-metastatic non-small cell lung cancer sublines in comparison with parent 
or highly bone-metastatic sublines [111]. In melanoma, plasmin was proved to be a key determinant of 
crossing of the BBB and formation of brain metastasis [112]. Moreover, we have shown that during 
migration of melanoma cells through the brain endothelium, tumor cells release large amounts of 
gelatinolytic serine proteases, including seprase. Inhibition of these proteases or silencing of seprase 
could significantly reduce the number of extravasating melanoma cells [54]. 
3.6.3. Heparanase 
Heparanase is an endoglycosidase, degrading heparan sulfate proteoglycans, being a critical 
mediator of tumor cell proliferation, angiogenesis, invasion and metastasis. This is achieved by 
remodeling of the extracellular matrix, releasing growth factors, chemokines, angiogenic factors, 
bioactive cell-surface heparin sulfate fragments and through non-enzymatic (signaling) activities [113]. 
Heparanase is considered a critical molecular determinant of brain metastasis [114] in melanoma [115] 
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and breast cancer [116], but surprisingly high exogenous heparanase concentrations were shown to 
downregulate invasion of brain metastatic melanoma cells [117]. Besides tumor cells, astrocytes were 
found to produce heparanase as well, significantly contributing to the brain colonization of melanoma 
cells [118]. 
3.7. Signaling Pathways Involved in Tumor-endothelial Interactions in the Brain 
In order to be able to respond adequately to extracellular stimuli, cerebral endothelial cells are 
equipped with a whole set of receptors and signaling molecules [119–121], reviewed in: [122]. This 
may contribute to a considerable heterogeneity of cerebral endothelial cells as well [123]. 
Transendothelial migration of tumor cells requires the active involvement of both tumor and 
endothelial cells. Understanding the pathways activated both in tumor cells and in endothelial cells 
will help to identify molecular targets for cancer therapy. 
3.7.1. Rho/Rac Signaling 
During invasion of tissues and migration through vessel walls and ECM components, metastasizing 
tumor cells require increased motility, which is dependent on the remodeling of the cytoskeleton. In 
this respect, members of the Rho family small GTPases were shown to have an indispensable role by 
regulating the two major modes of tumor cell movement, characterized by mesenchymal and amoeboid 
phenotype. The mesenchymal type of tumor cell movement requires elevated Rac1 activation and 
reduced Rho/ROCK signaling and is characterized by elongated cell morphology, formation of large 
membrane protrusions and dependence on integrins and extracellular proteolysis. On the other hand, 
the amoeboid migration type mimics movement of leukocytes, with a rounded morphology and 
generation of Rho/ROCK-dependent actomyosin contractile forces [124–126]. Interplay between these 
two types of tumor cell motility was shown to regulate movement of tumor cells during invasion of the 
extracellular matrix; however, little is known about the behavior of tumor cells meeting other types of 
barriers, i.e., during intravasation into circulation and extravasation into diverse tissues, including 
transmigration through the BBB. It has been shown that inhibition of ROCK decreases the migration 
of small cell lung cancer cells through the brain endothelium [127]. This effect, however, is not due to 
changes in tumor cell movement, since Rho/ROCK signaling, cytoskeletal reorganization and the 
concomitant changes of the tight junctions of endothelial cells were responsible for the decrease of 
transendothelial migration of tumor cells. This, in turn, highlights the importance of endothelial cells 
in the extravasation of tumor cells, clearly indicating that the endothelium forms not only a passive 
barrier for metastatic cells, but takes an active part in the process. 
3.7.2. Src Signaling 
Src family members are known to participate in many aspects of tumor progression and metastasis. 
In tumor cells, Src kinase may participate in the promotion of mesenchymal and inhibition of 
amoeboid motility [128] and in the phosphorylation of N-cadherin and dissociation of β-catenin during 
transendothelial migration [88]. Src kinases are known to regulate interendothelial junctions and 
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endothelial permeability as well [129,130]; therefore, it would be interesting to understand whether 
(brain) endothelial Src signaling is involved in metastasis formation. 
3.7.3. The PI3K-Akt-PTEN Pathway 
The PI3K-Akt pathway is a crucial regulator of cell survival and proliferation, and increased PI3K 
activity has been reported in several cancer types. In a recent study, a novel inhibitor of downstream 
PI3K was found to effectively control metastatic growth of HER2 positive breast cancer cells in 
multiple organs and resulted in a significant proportion of mice free from brain and bone metastases [131]. 
In addition, brain metastases of melanoma were shown to have significantly higher levels of 
phosphorylated Akt and lower PTEN than lung or liver metastases [132]. This pathway was shown to 
be activated not only in brain metastatic melanoma cells, but also in brain endothelial cells coming in 
contact with melanoma cell-conditioned media, inducing increased endothelial cell proliferation and 
motility [133]. Moreover, the PI3K inhibitor LY294002 was shown to reduce the number of  
ECM-invading breast cancer cells in the presence of pulmonary microvascular endothelial cells [134]. 
It was also shown that melanoma cell-associated VE-cadherin breakdown in HUVECs was not 
sensitive to LY294002, whereas transendothelial migration of melanoma cells was reduced in the 
presence of the PI3K inhibitor [135]. However, inhibition of PI3K had no effect on the transmigration 
of small cell lung cancer cells through brain endothelial cells [127]. 
3.7.4. Other Pathways Implicated in Brain Metastasis Formation, Transendothelial Migration or 
Invasion of Brain Metastatic Tumor Cells 
In the search for the determinants of brain metastasis formation, a few other signaling pathways 
have been described, which might be involved in the migration of tumor cells through the BBB. 
Recently, overexpression of endothelin receptor B was shown to result in an increased incidence of 
spontaneous CNS metastases of melanoma [136]. In melanoma, TGF-β2 was found to be crucial as 
well, since its expression is indispensable for the formation of parenchymal metastases [137]. Stat3 
activation was found to play an important role in angiogenesis, invasion and brain metastasis formation 
of melanoma cells through dysregulated expression of bFGF, VEGF and MMP-2 [105]. In breast cancer 
cells HER2 (EGFR2), positivity was found to contribute to brain metastatic colonization [138], the 
HER2 transfectants giving a significantly increased number of macrometastases. Taking into account 
that the BBB prevents the delivery of trastuzumab (a HER2 monoclonal antibody used for the 
treatment of mammary tumors), HER2 positive breast cancer patients have an increased risk of 
mortality caused by brain metastases. Besides HER2 positivity, breast cancers with increased risk to 
develop brain metastasis are more likely to be estrogen receptor negative, to express the basal 
cytokeratin CK5/6 and to overexpress EGFR [139]. Mutations in EGFR have been implicated in the 
pathogenesis of another brain metastasis-giving tumor type, the non-small cell lung carcinoma. An 
increased risk of progression in the CNS was found in advanced non-small cell lung cancer with EGFR 
mutations [140]. In lung adenocarcinoma, activation of the canonical WNT/TCF pathway through 
LEF1 and HOXB9 was identified as a key element of metastasis formation to brain and bone [141]. 
There are several signaling mechanisms implicated in the proliferation, invasion or migration of 
tumor cells, which—although not investigated so far—might be involved in the migration of tumor 
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cells through the BBB. The multidrug transporter P-glycoprotein, for example, has been shown to 
mediate the invasion of melanoma cells. P-gp was shown to cooperate with CD44 through the 
activation of MAP-kinases, leading to increased MMP activities [142]. Moreover, the MAP-kinase 
signaling pathways (including the mutations in BRAF) are critical in the development and progression 
of primary and brain metastatic melanoma; however, their role in the transendothelial migration of 
tumor cells has not been documented. ERK1/2 was shown to be activated in brain endothelial cells 
coming in contact with melanoma cell-conditioned media [133]. In melanoma, another pathway, 
phospholipase C signaling, might also be important, since it was shown to be involved in melanoma 
cell-induced endothelial junction disassembly in HUVECs [135]. Other promising targets might be 
receptor tyrosine kinases, e.g., Axl, which is highly expressed in several tumor types, including brain 
metastatic tumors [143] and cerebral endothelial cells as well [144]. Axl confers aggressive tumor 
behavior, leading to dissemination and metastasis formation [145]; however, no data are available 
about the role of Axl in brain metastasis formation. 
3.8. Role of Astrocytes in Brain Metastasis Formation 
Astrocytes have an indispensable role in the maintenance of BBB properties of cerebral endothelial 
cells. Therefore, they support endothelial cells in impeding tumor cells from penetrating into the brain. 
On the other hand, astrocytes have a protective role for brain metastases. Reactive astrocytes 
immediately localize to individual breast cancer cells even before extravasation and continue to 
associate with metastatic cells during the transmigration process and throughout the growth of the 
lesions [51]. Reactive astrocytes induce the protection of tumor cells from chemotherapy through 
sequestration of calcium from the cytoplasm of tumor cells and by upregulating survival genes in tumor 
cells [146,147]. Moreover, astrocytes secrete soluble factors that stimulate the proliferation of tumor 
cells in the brain microenvironment. In this respect, neurotrophins have a special importance in 
supporting the growth of melanoma cells [148]. In addition, astrocytes were shown to induce 
proliferation of lung and breast cancer cells by producing IL-1β, TNF-α and/or IL-6 [149,150]. Since 
inflammation was found to foster proliferation, survival and migration of tumor cells [151] and 
metastatic cells are also able to use several similar transendothelial migratory mechanisms as 
leukocytes, it is tempting to speculate that these proinflammatory cytokines secreted by astrocytes 
might not only induce proliferation of tumor cells, but also support the transendothelial migration and 
formation of new metastatic colonies in the brain. Astrocytes also produce heparanase, which was 
shown to contribute to the brain-metastatic specificity of melanoma cells [118], and MMP-9, which 
can support invasion of tumor cells and release growth factors from the extracellular matrix [51]. 
4. Conclusions 
Tumor cells meet a supportive environment in the brain parenchyma, protected from 
chemotherapeutics and antitumoral immune response and containing soluble factors favoring their 
survival and proliferation. It is not surprising, therefore, that brain metastases of malignant tumors 
have limited therapeutic options. Hence, it would be of crucial importance to prevent the formation of 
brain metastases. One of the possible strategies is to target the step of migration of metastatic cells 
through the blood-brain barrier. The mechanisms of this process are largely uncharacterized; however, 
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besides preventing cancer cells from entering the brain, brain endothelial cells seem to also play a 
protective role for metastatic cells during extravasation. Understanding these mechanisms is 
indispensable to find targets of prevention of brain metastasis formation. 
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